Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Launched by SYMETIS SA · Nov 28, 2014
Trial Information
Current as of April 28, 2025
Completed
Keywords
ClinConnect Summary
The SAVI TF is s single arm, multicenter, non-randomized and open registry. The purpose of this registry is to collect and monitor ongoing safety and performance data from commercial use of the ACURATE neo™ Aortic Bioprosthesis and ACURATE TF™ Transfemoral Delivery System.
The ACURATE neo™ and its Transfemoral Delivery System are intended for use in minimally invasive, transcatheter aortic valve replacement (TAVR) using transfemoral access in patients presenting with severe aortic valve stenosis.
The primary objective is to further evaluate the safety and performance of the ACURATE neo™ A...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient is included in the registry if eligible for transcatheter treatment of severe aortic stenosis with the ACURATE neo™ Aortic Bioprosthesis and ACURATE TF™ Transfemoral Delivery System as per the Instructions for Use
- • 2. Patient is willing to participate in the study, provides signed Informed Consent/Data Authorization Form and authorizes the sharing of data in the registry
- • 3. The subject and treating physician agree the subject will return for all required post-procedure follow-up visits
- Exclusion Criteria:
- • 1. Patients are excluded from the registry if they are not eligible for transcatheter treatment of severe aortic stenosis with the ACURATE neo™ Aortic Bioprosthesis and ACURATE TF™ Transfemoral Delivery System as per the Instructions For Use.
About Symetis Sa
Symetis SA is a pioneering medical device company specializing in innovative solutions for structural heart diseases. With a strong focus on transcatheter interventions, Symetis develops advanced technologies aimed at improving patient outcomes and enhancing the quality of care in cardiovascular medicine. The company is committed to rigorous clinical research and development, collaborating with healthcare professionals and institutions to ensure the safety and efficacy of its products. Through its dedication to innovation and excellence, Symetis SA strives to lead the way in transforming the treatment landscape for patients with heart conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Helge Möllmann, Prof.
Principal Investigator
Kerckhoff Klinik
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials